TUXEDO-3

MULTICENTER, SINGLE-ARM, 3 COHORT, PHASE II TRIAL OF HER3-DXd IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM METASTATIC BREAST CANCER AND NON-SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM ADVANCED SOLID TUMORS

CLINICAL TRIAL DETAILS

TO ANALYZE THE EFFICACY OF PATRITUMAB DERUXTECAN (HER3-DXd) AS DETERMINED BY INTRACRANIAL OBJECTIVE RESPONSE RATE (ORR-IC) PER LOCAL INVESTIGATOR AS JUDGED BY BEST CNS RESPONSE ACCORDING TO RANO-BM CRITERIA IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM METASTATIC BREAST CANCER (COHORT 1) AND ADVANCED NSCLC (COHORT 2), AND TO ASSESS OVERALL SURVIVAL AT 3 MONTHS IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM ADVANCED SOLID TUMORS (COHORT 3).

TUXEDO-3 AT CLINICATRAILS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

Breast cancer and NSCLC with brain metastases; Leptomeningeal disease

Spain, Austria

Follow up

PRESS RELEASE

SCIENTIFIC IMPACT

ASCO 2024 poster

ASCO 2024 lay language summary

ASCO 2025 presentation

ASCO 2025 lay language summary

Nature Medicine 2025 publication (select results) | Neuro-Oncology 2025 publication

BLOG ARTICLES RELATED

TRIAL SITES

Hospital Arnau de Vilanova de Valencia (Spain) Hospital Universitari Dexeus (Spain) Hospital Quirónsalud Sagrado Corazón (Spain) Hospital Ruber Internacional (Spain) Hospital Universitari Vall D’Hebron (Spain) Hospital Universitario Virgen del Rocío (Spain) Medical University of Vienna (Austria) Medizinische Universität Innsbruck (Austria) Salzburg Cancer Research Institute (Austria)